| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), NVAX's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 300.3K | - | - | |
| VP | 157.1K | - | - | |
| CFO | 136.5K | - | - | |
| VP | 101.4K | - | - | |
| Dir | 73.2K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2015 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 8,388 | $2.28 | $19,124.64 | +29.3% | |
| Jan 31, 2015 | Erck Stanley C86 | CEO And President | Buy | 6,122 | $2.28 | $13,958.16 | +6.7% |